Evidence map›Paper›PMID 28212531›Full record

SynthesisOncotarget2017

MSMB gene rs10993994 polymorphism increases the risk of prostate cancer.

Tao Peng, Lifeng Zhang, Lijie Zhu, Yuan-Yuan Mi

Open access · diamondAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. PPAR research · 2023
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Tao PengDepartment of Urology, The Third Affiliated Hospital of Nantong University, Wuxi, PR China.
Lifeng ZhangDepartment of Urology, Changzhou No.2 People's Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu Province, PR China.
Lijie ZhuDepartment of Urology, The Third Affiliated Hospital of Nantong University, Wuxi, PR China.
Yuan-Yuan MiDepartment of Urology, The Third Affiliated Hospital of Nantong University, Wuxi, PR China.
Wuxi Third People's Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genome-wide association studies (GWASs) identified microseminoprotein-β (MSMB) gene rs10993994 polymorphism was significantly associated with prostate cancer (PC) risk. However, the association between MSMB gene rs10993994 polymorphism and PC risk remains controversial. Therefore, we performed a systematic review and meta-analysis by searching in the databases of PubMed, and Embase. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by using fixed-effect or random-effect models. A total of 11 publications containing 13 case-control studies for rs10993994 polymorphism were included in our analysis. Our data indicated that MSMB gene rs10993994 polymorphism was associated with an increased risk of PC. Stratification analyses of ethnicity suggested rs10993994 polymorphism increased the risk of PC among Caucasians, but not among Asians. In conclusion, this meta-analysis indicates that MSMB gene rs10993994 polymorphism increases the risk of PC.

Indexed as

AllelesGenetic Association StudiesGenetic Predisposition to DiseasePolymorphism, Single NucleotideCase-Control StudiesGenotypeHumansMaleOdds RatioProstatic NeoplasmsProstatic Secretory ProteinsPublication Biasbeta-microseminoproteinProstatic Secretory Proteinsmeta-analysisMSMBprostate cancerrs10993994single nucleotide polymorphism

Identifiers

PMID28212531
PMCPMC5438667
OpenAlexW2587804857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.